Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New drugs for multiple sclerosis: new treatment algorithms

New drugs for multiple sclerosis: new treatment algorithms Purpose of reviewTo discuss recent changes in the multiple sclerosis (MS) treatment algorithm and to present therapies currently in MS clinical trials.Recent findingsHigh efficacy disease modifying therapies are optimally beneficial when used in the early, inflammatory phase of MS. Bruton's tyrosine kinase has emerged as an important therapeutic target for both relapsing and progressive forms of MS. Multiple therapies targeting remyelination failed to provide conclusive evidence of broad therapeutic benefit; however, more targeted approaches offer hope that myelin repair might be achieved resulting in specific clinical improvements. Strategies targeting chronic Epstein–Barr virus infection and dysbiosis of the gut microbiome are the first to link microbial risk factors for MS and therapeutic interventions.SummaryA striking number of diverse treatments under investigation bodes well for development of better and more effective therapies in MS. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Neurology Wolters Kluwer Health

New drugs for multiple sclerosis: new treatment algorithms

Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/new-drugs-for-multiple-sclerosis-new-treatment-algorithms-lkYTHcGd8P

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
ISSN
1350-7540
eISSN
1473-6551
DOI
10.1097/wco.0000000000001063
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewTo discuss recent changes in the multiple sclerosis (MS) treatment algorithm and to present therapies currently in MS clinical trials.Recent findingsHigh efficacy disease modifying therapies are optimally beneficial when used in the early, inflammatory phase of MS. Bruton's tyrosine kinase has emerged as an important therapeutic target for both relapsing and progressive forms of MS. Multiple therapies targeting remyelination failed to provide conclusive evidence of broad therapeutic benefit; however, more targeted approaches offer hope that myelin repair might be achieved resulting in specific clinical improvements. Strategies targeting chronic Epstein–Barr virus infection and dysbiosis of the gut microbiome are the first to link microbial risk factors for MS and therapeutic interventions.SummaryA striking number of diverse treatments under investigation bodes well for development of better and more effective therapies in MS.

Journal

Current Opinion in Neurology – Wolters Kluwer Health

Published: Jun 1, 2022

References

  • Treatment of multiple sclerosis – success from bench to bedside
  • Treatment of multiple sclerosis: a review
  • Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
  • Alemtuzumab vs. interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
  • Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
  • Ocrelizumab vs. interferon beta-1a in relapsing multiple sclerosis
  • Ofatumumab vs. teriflunomide in multiple sclerosis
  • Long term evolution of multiple sclerosis disability in the treatment era
  • Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis
  • Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
  • Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
  • Initial high-efficacy disease-modifying therapy in multiple sclerosis. A nationwide cohort study
  • Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies
  • Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry
  • Induction vs. escalation in multiple sclerosis: a 10-year real world study
  • Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies
  • Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis
  • The role of Bruton's tyrosine kinase in the immune system and disease
  • The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review
  • The development of BTK inhibitors: a five-year update
  • Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis
  • Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)
  • Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
  • Remyelination in multiple sclerosis: from basic science to clinical translation
  • Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
  • A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis
  • Effect of MD1003 (pharmaceutical grade, high-dose biotin) in progressive multiple sclerosis (SPI2): a phase 3, randomised, double-blind, placebo-controlled trial
  • Remyelination trials: are we expecting the unexpected?
  • Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study
  • Repurposing domperidone in secondary progressive multiple sclerosis: a Simon 2-stage phase 2 futility trial
  • Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis
  • A randomized controlled double-blinded crossover trial of clemastine fumarate as a remyelinating therapy for multiple sclerosis
  • Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis
  • Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: a dose-ranging study with assessment of reliability of visual outcomes
  • The role of Epstein–Barr virus in the etiology of multiple sclerosis: a current review
  • Longitudinal analysis reveals high prevalence of Epstein–Barr virus associated with multiple sclerosis
  • Epstein–Barr virus in multiple sclerosis: theory and emerging immunotherapies
  • Epstein–Barr virus in oral shedding of children with multiple sclerosis
  • Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM
  • Epstein–Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation
  • B-cell enrichment and Epstein–Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis
  • Sustained clinical improvement in a subset of patients with progressive multiple sclerosis treated with Epstein–Barr virus-specific T cell therapy
  • An updated review of teriflunomide's use in multiple sclerosis
  • Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide
  • Vidofludimus calcium, a next generation DHODH inhibitor for the treatment of relapsing-remitting multiple sclerosis
  • IMU-838, a developmental DHODH inhibitor in phase II for autoimmune disease, shows anti-SARS-CoV-2 and broad-spectrum antiviral efficacy in vitro
  • Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood–brain barrier integrity and by modulating the peripheral immune response
  • Efficacy and safety of masitinib in progressive forms of multiple sclerosis: a randomized, phase 3, clinical trial
  • Safety and immune effects of blocking CD40 ligand in multiple sclerosis
  • The effectiveness of statins as potential therapy for multiple sclerosis: a systematic review of randomized controlled trials
  • Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
  • Role of B cells in multiple sclerosis and related disorders
  • Antigen specific immune tolerance in multiple sclerosis-promising approaches and how to bring them to patients
  • The role of the gut microbiome in multiple sclerosis risk and progression: towards characterization of the ‘MS microbiome’
  • Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: a systematic review
  • The impact of IgA and the microbiota on CNS disease
  • A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetylcysteine
  • Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)
  • Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis
  • The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis